Use of Model‐Based Meta‐Analysis to Inform the Design of Early Clinical Trials of Anti‐Amyloid Beta Therapies in Alzheimer's Disease
ABSTRACT To inform an efficient development of new investigational anti‐amyloid beta (anti‐Aβ) monoclonal antibodies (mAbs), a modeling‐and‐simulation‐based strategy was proposed. A general modeling framework that links drug exposures to the time course of amyloid plaque removal and amyloid‐related...
Saved in:
Main Authors: | Sagar S. Bachhav, Ana Victoria Ponce‐Bobadilla, Diana Clausznitzer, Sven Stodtmann, Hao Xiong |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-07-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Subjects: | |
Online Access: | https://doi.org/10.1002/psp4.70038 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
by: Ronald C. Petersen, et al.
Published: (2025-04-01) -
Anti-Amyloid Aggregation Effects of Gobaishi (<i>Galla chinensis</i>) and Its Active Constituents
by: Sharmin Akter, et al.
Published: (2025-06-01) -
AhR regulation of amyloid beta-induced inflammation in astrocyte cells
by: Emmanuel Ojo, et al.
Published: (2025-07-01) -
Anti-amyloid Monoclonal Antibodies for Alzheimer’s Disease: A New Hope? (Review)
by: I. A. Mazerkina
Published: (2025-04-01) -
Generating real‐world evidence in early Alzheimer's disease: Considerations for applying the target trial emulation framework to study the safety of anti‐amyloid therapies
by: Xiaojuan Li, et al.
Published: (2025-04-01)